Terms: = Small Cell Lung Cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
7648 results:
1. Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.
Boyer M; Hui R; Urban D; Clingan P; Su WC; Devaux C; Gadgeel S; Garassino M; Leopold L; Daniel J; Munteanu MC; Samkari A; Luo Y; Abreu DR
BMC Cancer; 2024 Jul; 23(Suppl 1):1250. PubMed ID: 39054462
[TBL] [Abstract] [Full Text] [Related]
2. Comparison of treatment outcome between first-line combination immunotherapy (anti-PD-L1 or anti-PD1) with or without chemotherapy and chemotherapy alone in advanced non-small cell lung cancer patients in tertiary care hospital.
Naratornsirakul D; Chewaskulyong B; Kongkarnka S; Oranratnachai S
Cancer Med; 2024 Jul; 13(14):e70007. PubMed ID: 39030820
[TBL] [Abstract] [Full Text] [Related]
3. Nephrotoxicity of targeted therapy used to treat lung cancer.
Li Q; Lin J; Hao G; Xie A; Liu S; Tang B
Front Immunol; 2024; 15():1369118. PubMed ID: 39026680
[TBL] [Abstract] [Full Text] [Related]
4. A non-enhancing, T2 fluid-attenuated inversion recovery hyperintense, diffusion-restricting brainstem lesion in an egfr tyrosine kinase inhibitor-treated non-small-cell lung cancer patient.
Yuen CA; Bao S; Kong XT
Biomark Med; 2024; 18(9):431-439. PubMed ID: 39007837
[TBL] [Abstract] [Full Text] [Related]
5. Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with egfr L718Q mutation: A two-case report.
Li J; Jin M; Diao Y; Li X
Medicine (Baltimore); 2024 Jul; 103(28):e38789. PubMed ID: 38996163
[TBL] [Abstract] [Full Text] [Related]
6. Anticancer activity of Araguspongine C via inducing apoptosis, and inhibition of oxidative stress, inflammation, and egfr-TK in human lung cancer cells: An in vitro and in vivo study.
Li Z; Yu H; Hussain SA; Yang R
J Biochem Mol Toxicol; 2024 Jul; 38(7):e23763. PubMed ID: 38984790
[TBL] [Abstract] [Full Text] [Related]
7. Habitat radiomics and deep learning fusion nomogram to predict egfr mutation status in stage I non-small cell lung cancer: a multicenter study.
Wu J; Meng H; Zhou L; Wang M; Jin S; Ji H; Liu B; Jin P; Du C
Sci Rep; 2024 Jul; 14(1):15877. PubMed ID: 38982267
[TBL] [Abstract] [Full Text] [Related]
8. A case of Ph
Zhang Q; Zhou JD; Ding H; Yang L; Lu C; Chu MQ; Qian J; Zhang TJ
BMC Med Genomics; 2024 Jul; 17(1):182. PubMed ID: 38978091
[TBL] [Abstract] [Full Text] [Related]
9. Protocol for a systematic review with prospective individual patient data meta-analysis in egfr-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration.
Robledo KP; Lefresne S; Soon YY; Sahgal A; Pinkham MB; Nichol A; Soo RA; Parmar A; Hegi-Johnson F; Doherty M; Solomon BJ; Shultz DB; Tham IW; Sacher AG; Tey J; Leong CN; Koh WY; Huang Y; Ang YLE; Low J; Yong C; Lim MC; Tan AP; Lee CK; Ho C
BMJ Open; 2024 Jul; 14(7):e078335. PubMed ID: 38969367
[TBL] [Abstract] [Full Text] [Related]
10. Real-World treatment Patterns and Clinical Outcomes Among Patients with Metastatic or Unresectable egfr-Mutated Non-small cell lung cancer Previously Treated with Osimertinib and Platinum-Based Chemotherapy.
Patel J; Meng J; Le H; Tanaka Y; Phani S; Salas M; Wu C; Sternberg D; Esker S; Anderson JP; Crowley A; Zhou SQ; Lieb C; Sun H; Doan QV; Santhanagopal A; Reckamp KL
Adv Ther; 2024 Aug; 41(8):3299-3315. PubMed ID: 38958845
[TBL] [Abstract] [Full Text] [Related]
11. Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis.
Liu Y; Yalavarthi S; Yang F; Abdul-Rashid Y; Tang S; Long Z; Qin Y; Wu K; Wang Z
BMC Pulm Med; 2024 Jul; 24(1):309. PubMed ID: 38956553
[TBL] [Abstract] [Full Text] [Related]
12. The rapidly changing field of predictive biomarkers of non-small cell lung cancer.
Tóth LJ; Mokánszki A; Méhes G
Pathol Oncol Res; 2024; 30():1611733. PubMed ID: 38953007
[TBL] [Abstract] [Full Text] [Related]
13. A Visual Analysis of the Research Dynamics in Resistance to egfr Inhibitors for NSCLC.
Shao J; Gu Y; Guo R; Xu J
Drug Des Devel Ther; 2024; 18():2571-2591. PubMed ID: 38947223
[TBL] [Abstract] [Full Text] [Related]
14. Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies.
Figarol S; Delahaye C; Gence R; Doussine A; Cerapio JP; Brachais M; Tardy C; Béry N; Asslan R; Colinge J; Villemin JP; Maraver A; Ferrer I; Paz-Ares L; Kessler L; Burrows F; Lajoie-Mazenc I; Dongay V; Morin C; Florent A; Pagano S; Taranchon-Clermont E; Casanova A; Pradines A; Mazieres J; Favre G; Calvayrac O
Nat Commun; 2024 Jun; 15(1):5345. PubMed ID: 38937474
[TBL] [Abstract] [Full Text] [Related]
15. Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer.
Jarry U; Bostoen M; Archambeau J; Pineau R; Chaillot L; Jouan F; Solhi H; Ferrari H; Le Guevel R; Mennessier V; Lena H; Corre R; Ricordel C; Guillaudeux T; Pedeux R
PLoS One; 2024; 19(6):e0304914. PubMed ID: 38935790
[TBL] [Abstract] [Full Text] [Related]
16. Impact of Adjuvant Atezolizumab on Recurrences Avoided and treatment Cost Savings for Patients with Stage II-IIIA Non-small cell lung cancer in Canada.
Chu Q; Sripada K; Vaselenak S; Jovanoski N; Arnold M
Curr Oncol; 2024 Jun; 31(6):3301-3310. PubMed ID: 38920734
[TBL] [Abstract] [Full Text] [Related]
17. IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer.
Lu H; Ai J; Zheng Y; Zhou W; Zhang L; Zhu J; Zhang H; Wang S
Cell Death Dis; 2024 Jun; 15(6):447. PubMed ID: 38918360
[TBL] [Abstract] [Full Text] [Related]
18. High-dose furmonertinib combined with intraventricular chemotherapy as salvage therapy for leptomeningeal metastasis from egfr exon 20 insertion-mutated lung cancer.
Yu C; Xu T; Fang H; Wang X; Liu N; Yang L; Fang S
J Neurooncol; 2024 Aug; 169(1):203-213. PubMed ID: 38916849
[TBL] [Abstract] [Full Text] [Related]
19. Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect.
Lu C; Gao Z; Wu D; Zheng J; Hu C; Huang D; He C; Liu Y; Lin C; Peng T; Dou Y; Zhang Y; Sun F; Jiang W; Yin G; Han R; He Y
J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38908857
[TBL] [Abstract] [Full Text] [Related]
20. Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancer.
Melosky B; Vincent MD; McGuire AL; Brade AM; Chu Q; Cheema P; Martins I; Spicer JD; Snow S; Juergens RA
Int J Cancer; 2024 Sep; 155(6):963-978. PubMed ID: 38900018
[TBL] [Abstract] [Full Text] [Related]
[Next]
